Acadia Pharmaceuticals Inc Revenue Growth Rates (ACAD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Acadia Pharmaceuticals Inc   (NASDAQ: ACAD)
 

ACAD's Revenue Growth by Quarter and Year

Acadia Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACAD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 307.96
1st Quarter March 268.06
FY 576.02

ACADs Annual Revenue
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 1,071.51 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 957.80 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 726.44 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 517.24 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 484.15 millions




ACAD Revenue second quarter 2026 Y/Y Growth Comment
Acadia Pharmaceuticals Inc reported Revenue increase of 16.4% year on year in the second quarter 2026, to $ 307.96 millions, this is lower than Acadia Pharmaceuticals Inc 's recent average Revenue surge of 2280.39%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 109 other companies have achieved higher Revenue growth. While Acadia Pharmaceuticals Inc ' s Revenue growth of 16.4% ranks overall at the positon no. 2389 in the second quarter 2026.


ACAD Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 9.4 % 12.36 % 69.27 %
3rd Quarter September - 11.27 % 18.28 % 61.96 %
2nd Quarter June 16.4 % 9.34 % 46.43 % 22.8 %
1st Quarter March 9.72 % 18.7 % 73.75 % 2.59 %
FY   - 11.87 % 31.85 % -

Financial Statements
Acadia Pharmaceuticals Inc 's second quarter 2026 Revenue $ 307.96 millions ACAD's Income Statement
Acadia Pharmaceuticals Inc 's second quarter 2025 Revenue $ 264.57 millions Quarterly ACAD's Income Statement


ACAD Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 1.92 % 3.67 % 9.14 %
3rd Quarter September - 5.31 % 3.49 % 28.12 %
2nd Quarter June 14.88 % 8.29 % 17.55 % 39.49 %
1st Quarter March -5.61 % -5.89 % -10.91 % -13.21 %
FY (Year on Year)   - 11.87 % 31.85 % -


Back to ACAD Growth rate Comparisons >> Back to ACAD Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #110
Healthcare Sector #342
Overall #2389

Revenue Y/Y Growth Statistics
High Average Low
53363.93 % 2280.39 % -99.87 %
(Mar 31 2017)   (Dec 31 2015)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #110
Healthcare Sector #342
Overall #2389
Revenue Y/Y Growth Statistics
High Average Low
53363.93 % 2280.39 % -99.87 %
(Mar 31 2017)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Acadia Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
313233.33 % 5491.44 % -99.99 %
(Dec 31 2014)  


ACAD's II. Quarter Q/Q Revenue Comment
Acadia Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 14.88% quarter on quarter, to $ 307.96 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 8.29% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Acadia Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 640.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #640
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #640
Revenue Q/Q Growth Statistics
High Average Low
313233.33 % 5491.44 % -99.99 %
(Dec 31 2014)  


ACAD's II. Quarter Q/Q Revenue Comment
Acadia Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 14.88% quarter on quarter, to $ 307.96 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 8.29% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Acadia Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 640.


Acadia Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,138.64 $ 1,095.25 $ 1,071.50 $ 1,047.12 $ 1,018.89
Y / Y Revenue Growth (TTM) 11.75 % 9.93 % 11.87 % 12.69 % 14.41 %
Year on Year Revenue Growth Overall Ranking # 1143 # 269 # 109 # 45 # 172
Seqeuential Revenue Change (TTM) 3.96 % 2.22 % 2.33 % 2.77 % 2.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 2389 # 2054 # 953 # 500 # 838


Cumulative Revenue growth Comment
Although Acadia Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 2280.39% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 11.75% year on year, from 9.93% in Mar 31 2026.

In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 269 to 1143.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 110
Healthcare Sector # 211
Overall # 1143

Revenue TTM Y/Y Growth Statistics
High Average Low
53363.93 %
 2280.39 %
-99.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 342
S&P 500 # 2389
Cumulative Revenue growth Comment
Although Acadia Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 2280.39% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 11.75% year on year, from 9.93% in Mar 31 2026.

In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 269 to 1143.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 110
Healthcare Sector # 211
Overall # 1143

Revenue TTM Y/Y Growth Statistics
High Average Low
53363.93 %
2280.39 %
-99.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 342
S&P 500 # 2389




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACAD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions
Journey Medical Corp23.33%$ 23.326 millions
Twist Bioscience Corporation23.24%$ 23.235 millions
Axogen inc 23.06%$ 23.065 millions
Vericel Corporation22.48%$ 22.481 millions
Milestone Scientific Inc 22.28%$ 22.276 millions
Alpha Teknova Inc 22.05%$ 22.045 millions
X4 Pharmaceuticals Inc21.64%$ 21.642 millions
Exagen Inc 21.63%$ 21.629 millions
Adaptive Biotechnologies Corporation21.53%$ 21.526 millions


About Acadia Pharmaceuticals Inc Revenue Growth Rates (ACAD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Acadia Pharmaceuticals Inc (CIK 1070494).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-333243
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Acadia Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.